Format

Send to

Choose Destination
Nat Rev Cardiol. 2019 Jan;16(1):33-55. doi: 10.1038/s41569-018-0074-0.

Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles.

Bonora M1, Wieckowski MR2, Sinclair DA3,4, Kroemer G5,6,7,8,9,10,11, Pinton P12,13, Galluzzi L14,15,16.

Author information

1
Ruth L. and David S. Gottesman Institute for Stem Cell, Regenerative Medicine Research, Department of Cell Biology and Stem Cell Institute, Albert Einstein College of Medicine, Bronx, NY, USA.
2
Department of Biochemistry, Nencki Institute of Experimental Biology, Warsaw, Poland.
3
Department of Genetics, Paul F. Glenn Center for the Biology of Aging, Harvard Medical School, Boston, MA, USA.
4
Department of Pharmacology, School of Medical Sciences, The University of New South Wales, Sydney, New South Wales, Australia.
5
Equipe 11 labellisée Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.
6
INSERM, U1138, Paris, France.
7
Université Paris Descartes/Paris V, Paris, France.
8
Université Pierre et Marie Curie, Paris, France.
9
Metabolomics and Cell Biology Platforms, Gustave Roussy Comprehensive Cancer Center, Villejuif, France.
10
Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
11
Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.
12
Department of Morphology, Surgery, and Experimental Medicine, Section of Pathology, Oncology, and Experimental Biology, Laboratory for Technologies of Advanced Therapies, University of Ferrara, Ferrara, Italy. pnp@unife.it.
13
Maria Cecilia Hospital, GVM Care & Research, E.S. Health Science Foundation, Cotignola, Italy. pnp@unife.it.
14
Université Paris Descartes/Paris V, Paris, France. deadoc@vodafone.it.
15
Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA. deadoc@vodafone.it.
16
Sandra and Edward Meyer Cancer Center, New York, NY, USA. deadoc@vodafone.it.

Abstract

A large body of evidence indicates that mitochondrial dysfunction has a major role in the pathogenesis of multiple cardiovascular disorders. Over the past 2 decades, extraordinary efforts have been focused on the development of agents that specifically target mitochondria for the treatment of cardiovascular disease. Despite such an intensive wave of investigation, no drugs specifically conceived to modulate mitochondrial functions are currently available for the clinical management of cardiovascular disease. In this Review, we discuss the therapeutic potential of targeting mitochondria in patients with cardiovascular disease, examine the obstacles that have restrained the development of mitochondria-targeting agents thus far, and identify strategies that might empower the full clinical potential of this approach.

PMID:
30177752
PMCID:
PMC6349394
[Available on 2020-01-01]
DOI:
10.1038/s41569-018-0074-0

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center